Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial-Reference-Cited by-同舟云学术

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Published:2020-10 Issue:4 Volume:38 Page:489-499.e3
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Sharma Padmanee,Pachynski Russell K.^ORCID,Narayan Vivek,Fléchon Aude,Gravis Gwenaelle,Galsky Matthew D.,Mahammedi Hakim^ORCID,Patnaik Akash,Subudhi Sumit K.^ORCID,Ciprotti Marika,Simsek Burcin,Saci Abdel^ORCID,Hu Yanhua,Han G. Celine,Fizazi Karim

Funder

Ono Pharmaceutical

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference55 articles.

1. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade;Abida;JAMA Oncol.,2019

2. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study;Antonarakis;J. Clin. Oncol.,2020

3. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment;Attard;J. Clin. Oncol.,2018

5. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study;Beer;Eur. Urol.,2017

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in and prospects of immunotherapy for prostate cancer;Cancer Letters;2024-10

2. Identification of circadian clock-related immunological prognostic index and molecular subtypes in prostate cancer;Discover Oncology;2024-09-11

3. Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial;2024-09-11

4. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers;Nature Cancer;2024-09-06

5. Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model;Cancers;2024-08-14